Sofosbuvir is an antiviral medication available as a generic product and marketed under brand names such as Sovaldi. It belongs to the class of direct-acting antiviral agents that target hepatitis C virus (HCV) replication. In Hong Kong, Sofosbuvir is a prescription-only medicine and is regulated by the Department of Health. It is supplied as a 400 mg oral pill.
Sofosbuvir is a nucleoside analogue that specifically inhibits the HCV NS5B RNA-dependent RNA polymerase, an enzyme essential for viral RNA synthesis. By mimicking the natural substrate uridine, Sofosbuvir is incorporated into the growing viral RNA chain, causing premature termination of replication.
Sofosbuvir’s targeted mechanism allows it to suppress HCV across all genotypes, a key reason why it is a cornerstone of modern HCV therapy.
Sofosbuvir is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of chronic hepatitis C infection. Hong Kong’s regulatory authorities adopt the same indications. Approved regimens combine Sofosbuvir with other direct-acting antivirals (DAAs) to achieve a sustained virologic response (SVR), defined as undetectable HCV RNA 12 weeks after therapy completion.
Sofosbuvir is not indicated as monotherapy for HCV; it must be paired with another DAA such as ledipasvir, velpatasvir, or daclatasvir, depending on genotype and disease severity.
These reactions are generally self-limiting and do not necessitate discontinuation.
Patients with renal impairment (CrCl 30-60 mL/min) may require an adjusted regimen or alternative therapy under specialist guidance.
If viral load remains detectable, clinicians may adjust the regimen or extend therapy.
This article provides educational information about Sofosbuvir and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes. Sofosbuvir is designed to be combined with other direct-acting antivirals such as ledipasvir, velpatasvir, or daclatasvir. The specific partner drug and treatment duration depend on the HCV genotype and the presence of cirrhosis.
No. Sofosbuvir can be taken with or without food, and meals do not significantly alter its absorption.
Take the missed tablet as soon as you remember on the same day. Do not double the next dose; maintain the once-daily schedule.
Patients with a creatinine clearance of 30 mL/min or higher can generally use the standard 400 mg dose, but those with more severe renal impairment require careful assessment and may need an alternative regimen.
Vision changes are not a common side effect of Sofosbuvir alone. However, if Sofosbuvir is combined with certain other antivirals, rare ocular symptoms have been reported and should be reported to a clinician.
Yes. Sofosbuvir-based regimens are approved for use in HIV-HCV co-infection, provided that there are no drug-drug interactions with the patient’s antiretroviral therapy.
Most patients experience a gradual decline in ALT and AST levels within the first few weeks of therapy. Full normalization may occur by the end of treatment or shortly thereafter.
Alcohol is not a direct interaction, but ongoing heavy alcohol use can worsen liver disease and may impede treatment success. Discuss alcohol intake with your healthcare provider.
The generic 400 mg Sofosbuvir tablet is typically white, round, and imprinted with the dosage strength or manufacturer code. Appearance can vary by producer.
Sofosbuvir is not screened for in standard occupational drug testing programs because it is not a controlled substance and has no psychoactive properties.
